Macquarie Group’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.56M | Buy |
11,826
+806
| +7% | +$107K | 0.01% | 574 |
|
|
2025
Q4 | $1.56M | Sell |
11,020
-304,442
| -97% | -$44.1M | 0.01% | 611 |
|
|
2025
Q3 | $44.3M | Buy |
315,462
+44,960
| +17% | +$6.09M | 0.05% | 458 |
|
|
2025
Q2 | $34M | Buy |
270,502
+39,154
| +17% | +$4.49M | 0.04% | 510 |
|
|
2025
Q1 | $25.6M | Sell |
231,348
-42,778
| -16% | -$5.42M | 0.03% | 597 |
|
|
2024
Q4 | $37.4M | Sell |
274,126
-218,064
| -44% | -$27M | 0.05% | 482 |
|
|
2024
Q3 | $56.7M | Buy |
492,190
+221,213
| +82% | +$30.3M | 0.06% | 413 |
|
|
2024
Q2 | $37.3M | Sell |
270,977
-5,033
| -2% | -$690K | 0.04% | 497 |
|
|
2024
Q1 | $38.1M | Sell |
276,010
-52,119
| -16% | -$7.12M | 0.04% | 510 |
|
|
2023
Q4 | $43.2M | Buy |
328,129
+69,518
| +27% | +$8M | 0.05% | 473 |
|
|
2023
Q3 | $29.1M | Sell |
258,611
-816
| -0.3% | -$85.9K | 0.04% | 558 |
|
|
2023
Q2 | $24.5M | Sell |
259,427
-33,183
| -11% | -$3.24M | 0.03% | 604 |
|
|
2023
Q1 | $29.6M | Buy |
292,610
+7,296
| +3% | +$759K | 0.04% | 576 |
|
|
2022
Q4 | $34.1M | Sell |
285,314
-990
| -0.3% | -$116K | 0.04% | 564 |
|
|
2022
Q3 | $30.4M | Sell |
286,304
-6,586
| -2% | -$668K | 0.04% | 576 |
|
|
2022
Q2 | $28.6M | Sell |
292,890
-25,173
| -8% | -$2.32M | 0.03% | 620 |
|
|
2022
Q1 | $29.8K | Buy |
318,063
+65,302
| +26% | +$5.53M | 0.02% | 661 |
|
|
2021
Q4 | $21.5M | Buy |
252,761
+18,676
| +8% | +$1.72M | 0.02% | 733 |
|
|
2021
Q3 | $22.5M | Sell |
234,085
-2,371
| -1% | -$224K | 0.02% | 738 |
|
|
2021
Q2 | $23M | Buy |
236,456
+7,699
| +3% | +$738K | 0.02% | 748 |
|
|
2021
Q1 | $22.2M | Sell |
228,757
-2,783
| -1% | -$292K | 0.03% | 511 |
|
|
2020
Q4 | $22.2M | Sell |
231,540
-718,601
| -76% | -$69.4M | 0.03% | 491 |
|
|
2020
Q3 | $91.4M | Buy |
950,141
+37,532
| +4% | +$4.34M | 0.15% | 139 |
|
|
2020
Q2 | $111M | Buy |
912,609
+677,365
| +288% | +$74.9M | 0.19% | 102 |
|
|
2020
Q1 | $20.4M | Buy |
235,244
+298
| +0.1% | +$29.2K | 0.04% | 410 |
|
|
2019
Q4 | $25.3M | Buy |
234,946
+536
| +0.2% | +$56.1K | 0.04% | 453 |
|
|
2019
Q3 | $21.1M | Sell |
234,410
-7,272
| -3% | -$679K | 0.04% | 436 |
|
|
2019
Q2 | $20.4M | Buy |
241,682
+8,278
| +4% | +$680K | 0.03% | 455 |
|
|
2019
Q1 | $20.6M | Sell |
233,404
-38,731
| -14% | -$3.24M | 0.04% | 456 |
|
|
2018
Q4 | $19.4M | Sell |
272,135
-453,627
| -63% | -$43.5M | 0.04% | 433 |
|
|
2018
Q3 | $89.2M | Sell |
725,762
-108,387
| -13% | -$12.3M | 0.15% | 124 |
|
|
2018
Q2 | $81.9M | Buy |
834,149
+62,979
| +8% | +$5.64M | 0.14% | 135 |
|
|
2018
Q1 | $64M | Buy |
771,170
+61,249
| +9% | +$5.17M | 0.12% | 162 |
|
|
2017
Q4 | $55.1M | Sell |
709,921
-53,311
| -7% | -$3.64M | 0.1% | 200 |
|
|
2017
Q3 | $46.8M | Buy |
763,232
+4,535
| +0.6% | +$239K | 0.08% | 217 |
|
|
2017
Q2 | $34.9M | Sell |
758,697
-17,193
| -2% | -$834K | 0.06% | 288 |
|
|
2017
Q1 | $33.6M | Buy |
775,890
+143,825
| +23% | +$6.16M | 0.06% | 292 |
|
|
2016
Q4 | $24.5M | Sell |
632,065
-273,683
| -30% | -$12.4M | 0.05% | 376 |
|
|
2016
Q3 | $45.9M | Buy |
905,748
+645,748
| +248% | +$32.2M | 0.09% | 187 |
|
|
2016
Q2 | $11.8M | Buy |
260,000
+128,110
| +97% | +$5.9M | 0.01% | 671 |
|
|
2016
Q1 | $5.22M | Buy |
+131,890
| New | +$5.23M | 0.01% | 702 |
|
Other funds holding NBIX
VPM
VCM
Macquarie Group's NBIX Position: Q1 2026 in Review
Macquarie Group increased its Neurocrine Biosciences (NBIX) stake by 7.3% in Q1 2026, buying an estimated $107K and bringing the position to 11,826 shares worth $1.56M. The position accounts for 0.01% of the portfolio, ranked #574.
Macquarie Group first reported a position in NBIX in Q1 2016 and has held it in 41 quarters since. The position peaked at $111M in Q2 2020. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.
- Macquarie Group held 11,826 shares of Neurocrine Biosciences worth $1.56M as of Q1 2026.
- Macquarie Group bought 806 Neurocrine Biosciences shares in Q1 2026, an estimated $107K.
- Neurocrine Biosciences made up 0.01% of Macquarie Group's portfolio in Q1 2026, its #574 holding.
- Macquarie Group first reported a position in Neurocrine Biosciences in Q1 2016 and has held it in 41 quarters since.
- Macquarie Group's Neurocrine Biosciences position peaked at $111M in Q2 2020.
- 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.
Based on Macquarie Group's 13F filing for Q1 2026, filed 15 May 2026.